Hypernatremia

Canine Magician Makes Salted Dough Christmas Ornaments Disappear

Retrieved on: 
Mercredi, décembre 6, 2023
Vomiting, Pet, Hypernatremia, Toxicology, Risk, Thirst, Patient, Animal, Poisoning, Blood, Seizure, Water, Christmas, Drinking, Central nervous system, Lethargy, Nursing, Veterinary medicine, Medical imaging

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- Mary Mueller and her husband Paul Benson were enjoying a family day of baking after Christmas last year, making salted dough Christmas ornaments with their grandkids' handprints in them that would be tucked away for next year's tree. The holiday works of art were cooling on the counter when Mary noticed they had vanished.

Key Points: 
  • BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- Mary Mueller and her husband Paul Benson were enjoying a family day of baking after Christmas last year, making salted dough Christmas ornaments with their grandkids' handprints in them that would be tucked away for next year's tree.
  • "It was about 6 p.m. when we noticed the ornaments were missing and we knew our dog Shandy was the only one who could have taken them," explained Mary.
  • "At first, we weren't too concerned but then Shandy became very thirsty and started drinking large amounts of water.
  • The playful pooch from Hunt Valley, Maryland, had taken their son's medication bottle into the back yard, chewed off the top, and ingested the pills.

VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

Retrieved on: 
Mercredi, août 9, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Neutropenia, REMS, Maintenance, Hypermagnesemia, Cardiac arrest, Febrile neutropenia, Hypophosphatemia, Magnesium, Diarrhea, Mitigation, Hypocalcemia, Pharmacy, Food, QT interval, Indigestion, ECG, HSCT, Abdominal pain, QT, Sepsis, Acute myeloid leukemia, Alkaline phosphatase, Vomiting, Insomnia, AML, Lymphocytopenia, Patient, NE, Physician, Risk, Hypokalemia, Daiichi Sankyo, Anemia, HR, CR, Mucositis, Nausea, Hypernatremia, FLT3, Fungal infection, Upper respiratory tract infection, Lancet, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Safety, Headache, Thrombocytopenia, Nosebleed, Hyperkalemia, TSE, Disease, Pharmaceutical industry, Hypoalbuminemia

VANFLYTA was approved by the FDA on July 20, 2023 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive as detected by an FDA-approved test.

Key Points: 
  • VANFLYTA was approved by the FDA on July 20, 2023 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive as detected by an FDA-approved test.
  • The results of QuANTUM-First were published in The Lancet .1
    The safety of VANFLYTA was evaluated in 265 patients with newly diagnosed FLT3-ITD positive AML who received VANFLYTA once daily (35.4 mg with chemotherapy, 26.5 to 53 mg as maintenance) in the QuANTUM-First trial.
  • Daiichi Sankyo is committed to ensuring that patients in the U.S. who are prescribed VANFLYTA can access the medication and receive appropriate financial support.
  • Provider and patient support and information regarding distribution, access, and reimbursement are now available through Daiichi Sankyo Access Central by visiting www.DSIAccessCentral.com or calling 1-866-4-DSI-NOW (1-866-437-4669).

VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Retrieved on: 
Jeudi, juillet 20, 2023
Oncology, Health, FDA, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Magnesium, QT interval, Doctor of Philosophy, Alkaline phosphatase, Patient, Division, Risk, Daiichi Sankyo, HR, Leukemia, Nosebleed, Thrombocytopenia, REMS, Maintenance, Febrile neutropenia, Diarrhea, Pharmacy, Duke Cancer Institute, Sepsis, Vomiting, FLT3, Fungal infection, Lancet, Death, Headache, Safety, Neutropenia, Cardiac arrest, Indigestion, ECG, Abdominal pain, Acute myeloid leukemia, Insomnia, Lymphocytopenia, Anemia, CR, Mucositis, Hypermagnesemia, Hyperkalemia, Hypophosphatemia, Mitigation, Hypocalcemia, HSCT, QT, Bone marrow, AML, NE, Hypokalemia, Nausea, Hypernatremia, Upper respiratory tract infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, TSE, Pharmaceutical industry, Nursing, MD, Hypoalbuminemia

VANFLYTA will be available by prescription in the U.S. in the coming weeks.

Key Points: 
  • VANFLYTA will be available by prescription in the U.S. in the coming weeks.
  • VANFLYTA is approved with a Boxed WARNING for QT prolongation, torsades de pointes and cardiac arrest.
  • The FDA concurrently approved a companion diagnostic test to detect FLT3-ITD mutations in patients with newly diagnosed AML.
  • Daiichi Sankyo is committed to ensuring that patients in the U.S. who are prescribed VANFLYTA can access the medication and receive appropriate financial support.

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Retrieved on: 
Vendredi, mars 31, 2023
Infection, Risk, Civil service commission, Hearing loss, European Medicines Agency, Committee for Medicinal Products for Human Use, COG, Cisplatin, Committee, EMA, RESEARCH, Vomiting, FENC, Ototoxicity, Patient, Hypokalemia, Approval, Nausea, PARK, TSX, Hypernatremia, Energy Market Authority, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, European Commission, CHMP, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion and recommended granting a Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) – known as PEDMARK® in the U.S. – for the prevention of ototoxicity (hearing loss) induced by cisplatin chemotherapy in patients 1 month to

Key Points: 
  • ~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~
    ~ Pedmarqsi is Currently Marketed as PEDMARK® in the U.S.
  • The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.
  • The CHMP's recommendation will now be reviewed by the European Commission, ratification of the CHMP recommendation is expected by early June 2023.
  • PEDMARK was approved by the U.S. Food and Drug Administration (FDA) in September 2022.

Brian P. Murphy, Esq., Files OCR Complaint Against Bucks County Nursing Home Facility for Allegedly Withholding Medical Records

Retrieved on: 
Jeudi, juin 23, 2022
People, Complaint, Roger Hawkins (drummer), Hospital Records, Dehydration, Long-term care, Community, Chief complaint, PC, Office of Inspector General, U.S. Department of Health and Human Services, Mental health law, HIPAA, Injury, Health Insurance Portability and Accountability Act, Letter, Mouth ulcer, Family, Proofreading, Record, OCR, Hypernatremia, Esquire, Accountability Act, Falls, Malnutrition, Hospital, Private investigator, Medicine

DOYLESTOWN, Pa., June 23, 2022 /PRNewswire-PRWeb/ -- As a precursor to a potential wrongful death claim, The Law Firm of Brian P. Murphy, PC, has been retained to represent a family whose loved one was in a Bucks County nursing home, Briarleaf Nursing and Convalescent Center, now known as Liberty Pointe Rehabilitation and Healthcare Center.

Key Points: 
  • Brian P. Murphy, Esquire, is representing the family of an individual who was discharged from a Bucks County nursing home facility, Briarleaf Nursing and Convalescent Center.
  • Mr. Murphy sought medical records from the facility and, when they were not received in accordance with the law, he filed a civil rights complaint against Briarleaf.
  • To investigate the family's potential nursing home lawsuit with Briarfleaf, Mr. Murphy's firm sought the decedent's medical records.
  • 27288239), alleging that the law firm, in pursuit of its wrongful death claim, requested their client's medical records from Briarleaf Nursing and Convalescent Center.

Groundbreaking NYU Winthrop Study Shows Promise for Correcting Common Misdiagnoses of Hyponatremia That Can Cause Critical Patients to Deteriorate Further

Retrieved on: 
Mardi, décembre 11, 2018
Electrolyte disturbances, RTT, Sodium, Medicine, Hyponatremia, Cerebral salt-wasting syndrome, Hypernatremia

The study involves hyponatremia, a common disorder that occurs when the concentration of sodium in a person's blood becomes abnormally low.

Key Points: 
  • The study involves hyponatremia, a common disorder that occurs when the concentration of sodium in a person's blood becomes abnormally low.
  • The new study and its revelations on misdiagnoses may revolutionize the worldwide medical protocol among all physicians who treat patients with hyponatremia.
  • Our study showed that more than a third of these patients actually had cerebral salt wasting and were in dire need of hydration."
  • The NYU Winthrop Hospital study was co-authored by NYU Winthrop physicians Louis Imbriano, MD and Nobuyuki Miyawaki, MD.